SAB Biotherapeutics (NASDAQ:SABS) Downgraded to Strong Sell Rating by Zacks Research

Key Points

• Zacks Research downgraded SAB Biotherapeutics (NASDAQ:SABS) from a "hold" to a "strong sell", joining other recent downgrades from Wall Street Zen and Weiss Ratings.
• Shares fell about 9.6% after SAB reported a quarterly EPS loss of ($0.46) versus estimates of ($0.16); the stock trades around $4.15 with a market cap near $211 million and a 52‑week range of $1.00–$6.60.
• Analyst opinion is mixed — one Strong Buy, four Buy and two Sell — producing a MarketBeat average rating of "Moderate Buy" and an average target of $10, with individual price targets ranging up to $14.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) was downgraded by stock analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other analysts have also recently issued reports on SABS. Wall Street Zen cut SAB Biotherapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d)" rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Chardan Capital increased their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday. HC Wainwright reduced their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday. Finally, UBS Group assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $7.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.00.

SAB Biotherapeutics Stock Down 9.6%

Shares of SABS opened at $4.15 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 9.46. The company has a 50-day simple moving average of $4.02 and a 200-day simple moving average of $3.36. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60. The firm has a market capitalization of $211.44 million, a P/E ratio of -1.79 and a beta of 0.59.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, equities research analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

Several hedge funds have recently modified their holdings of SABS. Perceptive Advisors LLC bought a new position in SAB Biotherapeutics in the 4th quarter worth approximately $3,004,000. Millennium Management LLC bought a new position in SAB Biotherapeutics in the 4th quarter valued at $1,212,000. Balyasny Asset Management L.P. bought a new position in SAB Biotherapeutics in the 4th quarter valued at $1,778,000. ADAR1 Capital Management LLC increased its stake in shares of SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company's stock valued at $99,000 after buying an additional 11,344 shares during the period. Finally, ExodusPoint Capital Management LP bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth $322,000. 7.82% of the stock is owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.